Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The clinical beginning of diffuse pleural mesothelioma is a pleurisy. Initially pleura may be normal at X-ray examination, then either a pachypleuritis or a tumorous pleura appears. Thery serious since there is in the literature no cured case. The average survival time from diagnosis to death is 15 months. At terminal stage mesothelioma does not invade the other coelomic cavities. It may remain limited to the hemithorax where it has started, invading then the organs by contiguity. Metastasis may occur but their frequency is very variable, from 30 to 70% according the literature. On a therapeutic point of view all was tried: Surgery is rarely curative but may reduce temporarily effusion pain and dyspnea. Radiotherapy at high doses produces a partial effect in some series, but results are variable. Chemotherapy: adriamycin could be the most promising agent. At present time according to many authors no treatment seems to change the course of the disease.
Rev Fr Mal Respir
PMID:[Evolutive patterns of diffuse pleural mesothelioma (author's transl)]. 11 73

On the basis of 110 prostatic osteoses that were histologically proven, constantly painful and demonstrated by X-ray, treated by early estrogenotherapy using very high doses, backed up by a high-dose maintenance estrogenotherapy, the authors study the clinical, radiological, histological and biological profile of this metastatic cancer, as well as the response to treatment. The median actuarial survival time of the patients studied is 18.5 months. No statistically significant prognostic correlation was found. Only patients who are clinically estrogen-sensitive, are suffering from bone metastases without a combined visceral conditions, and have a normal initial rate of alcaline phosphates, tend to have a better prognosis (median actuarial survival 31 months versus 18.5 months for the overall population).
Rev Rhum Mal Osteoartic 1979 Dec
PMID:[Prostatic osteosis. Retrospective study of 110 cases treated with high-dose estrogens]. 11 98

The reported incidence of malignant pheochromocytoma varies from series to series. In this series 4 cases (7.2 p. 100) were observed out of a total of 55. In two cases the tumour progressed rapidly but in the other two cases, metastases were detected 3 to 12 years after the apparent cure of a histologically benign pheochromocytoma. The urinary levels of catecholamines and their metabolites gave no indication of the underlying malignancy. The diagnosis was only made from the clinical and radiological detection of metastases (2 hepatic, 2 bone). There is no satisfactory treatment and various therapeutic methods have to be used in succession; surgery for a single metastasis, radiotherapy and antiadrenergic agents to combat clinical manifestations. The natural history of this tumour is relatively long.
Arch Mal Coeur Vaiss 1979 Nov
PMID:[Malignant pheochromocytoma]. 11 18

A 5 years survival of 20% without local recurrence and/or metastasis was obtained after radiation therapy alone. This figure is slightly inferior to the survival rate of surgically treated tumours. Failure is mostly due to the appearance of metastases after radical treatment in spite of additional chemotherapy and/or immunotherapy. But experience has also shown that certain cancers "locally controlled" by radiation therapy can recur 3, 5, 8 or even more years later. Two thirds of squamous cell carcinomas are sterilized with doses of 60 Gy. A dose of 80-90 Gy has a greater curative effect on tumours usually unresponsive to doses of 60 Gy. But this level of radiation results in significant damage to normal tissue with inacceptable complications. Even with such doses, quiescent cells and hypoxic cells remain unresponsive. These cell populations are both clonogenic later. Megavoltage therapy must therefore be associated with chemical and physical radiosensitizing agents (e. g. hyperthermia and drugs of the nitro-imidazole group). Treatment protocols also fully exploit the biological effect of chemotherapy recruitment, cell synchronisation and synergistic lethal effect. The biological effects to neutrons on hypoxic cells were also explored, as most of the latter respond to neither X nor kappa therapy. In all, the new treatment strategy must seek the complementarity of the specific biological effects or radiotherapy chemotherapy and radiosensitizing agents (chemical and/or physical). The goal is a 10% growth rate in the cure of squamous cell carcinomas.
Rev Fr Mal Respir 1979 Dec
PMID:[The use of potentiating agents in megavoltage therapy of non-resected localized carcinoma of the lung (author's transl)]. 12 19

Vertebral chordomas develop from the intrarachidial -- and more often the intrasomatic --vestiges of the embryonic notochord, and are rare caancers that are more likely to become manifest, usually between 30 and 40 years of age, with a painful radiculo-medullary syndrome than with the clear signs of a tumour. The insidious evolution of this type of cancer, which gives rise to few metastases, and its ambiguous radiological appearance explain why it is usually diagnosed late after an anatomo-pathological examination. The fundamental histological element is the physaliphorous cell, ultrastructural studies of which have demonstrated that the large "mucous" inclusions of interstitial material. The discovery, by Murad and Murthy, of particles enclosed in a membrane in the chordomatous cells indicates possible viral involvement. Radio-surgical treatment results in more comfortable survival (very variable) although it involves repeated high-dose cobalto-therapy and repeated surgical excisions.
Rev Rhum Mal Osteoartic 1975 Apr
PMID:[Spinal chrodoma - III. Review of the literature since 1960]. 16 25

The authors describe the possibilities and the limitations of the "scanner" in spinal pathology. Use of the third dimension and the certainty of absolute measurements, make this a very interesting method that can be applied to several areas of spinal pathology, especially traumatology and detection of primary and secondary tumors. It seems that this technique may be used in particular in the study of canal stenoses. There are future possibilities in view for segmentary densitometry, which gives better results than overall scintigraphy, especially in locating metastases. At present, studies are underway using contrast solution in order to study the possibilities of interpreting the content-container relationship.
Rev Rhum Mal Osteoartic 1979 May
PMID:[Tomodensitometry and spinal pathology]. 31 9

The usual form of chemotherapy of metastatic small cell lung cancer gives a 50% objective response with a mean survival of 7-8 months. We have tested a new antimitotic drug using pirarubicin alone in 26 patients. After the second treatment we noticed a response level of 12% with moderate toxicity. Then, we undertook classical chemotherapy using cisplatin-V16. After 3 doses the response level was 50% with a median survival of 32 weeks. In our study the use of a single drug pirarubicin in metastatic small cell cancer did not appear to worsen the chance of survival in patients if polychemotherapy was carried out immediately in cases which failed on the single drug. Our monotherapy did not appear to induce resistance to affective polychemotherapy. This method applied carefully to patients with metastatic disease with a strict follow up may be utilised in the assessment of the efficacy of the newer antimitotic drugs.
Rev Mal Respir 1992
PMID:[A phase II trial of pirarubicin in untreated disseminated small cell lung cancer. A cooperative study of the French Pneumo-Cancerology Group]. 131 4

Data from 452 patients who underwent pulmonary resection for a non small cell bronchogenic carcinoma from 1980 to 1985 were analysed retrospectively. The operative mortality rate was 5.5%. Mortality was significantly increased in patients who underwent enlarged resections for T4 tumors (20%; p < or = 0.05), and in patients who were 70 years and older (12.8%; p < or = 0.05). The overall 5-years survival rate was 32.7% at 5 years. Prognosis in patients who were 70 years and older was similar to that in younger patients. No difference in survival was observed in patients with lymph node metastases with regard to the operative procedure (pneumonectomy versus lobectomy). Survival in patients without lymph node metastases who underwent a lobectomy was similar to those who underwent a conservative resection. Prognostic significance of the histologic cell type and the tumor formula (pTNM) was assessed by multivariable analysis. There were statistically significant differences between squamous cell carcinoma and both adenocarcinoma (p < or = 10(-5)) and undifferentiated carcinoma (p < or = 0.01). This study confirmed the validity of the TNM classification (4th ed) for the accurate prognosis evaluation. Lymph node involvement appeared to be the most pejorative factor (p < or = 10(-5)).
Rev Mal Respir 1992
PMID:[Results of surgery of non-small cell primary bronchial cancers. Retrospective analysis of 452 resections]. 133 49

MRI is the technique of choice to detect cerebral metastases. Double-dose delayed CT is the optimal CT examination to be performed in case of limited access to MRI. If the examination shows the presence of multiple metastases, MRI is not necessary. If CT shows an apparently single lesion, an MRI examination is essential, considering the number of lesions detected by MRI and not seen with CT.
Rev Mal Respir 1992
PMID:[How can metastatic extension be assessed in the brain?]. 133 73

The first intention imaging modality for detecting bone metastases of non small cell (NSC) bronchogenic carcinoma is bone scintigraphy using technetium-99m pyrophosphate or diphosphonates. This test has a high sensitivity but equivocal images may lead to complementary tests including magnetic resonance imaging (MRI) or bone biopsy. Based on bone metastases prevalence, scintigraphy is recommended for patients entering a therapeutic trial, having bone pain, having a non characteristic bone abnormality on radiography or CT, having a non epidermoid histology or having associated pathologies increasing the risk of surgery. The utility of bone scan is questionable for patients having a Stage I or II epidermoid cancer, having already evidence of bone metastases or for whom the result of the bone scan will not change the therapeutic management. After a negative bone scan, there will be probably an indication for MRI at search of small infra-scintigraphic osteo-medullary metastases.
Rev Mal Respir 1992
PMID:[How can metastatic bone involvement be assessed?]. 133 74


1 2 3 4 5 6 7 8 9 10 Next >>